Published in World J Hepatol on April 27, 2012
Interactions between the intestinal microbiome and liver diseases. Gastroenterology (2014) 1.92
The gut microbiota and host health: a new clinical frontier. Gut (2015) 1.91
Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol (2012) 1.61
Cell signals influencing hepatic fibrosis. Int J Hepatol (2012) 0.98
Pancreatic cancer, inflammation, and microbiome. Cancer J (2014) 0.91
Linking intestinal homeostasis and liver disease. Curr Opin Gastroenterol (2013) 0.90
Liver Injury and the Activation of the Hepatic Myofibroblasts. Curr Pathobiol Rep (2013) 0.89
The Characterization of Novel Tissue Microbiota Using an Optimized 16S Metagenomic Sequencing Pipeline. PLoS One (2015) 0.88
Comparing the effects of acute alcohol consumption in germ-free and conventional mice: the role of the gut microbiota. BMC Microbiol (2014) 0.88
Host-microbiome interactions in alcoholic liver disease. Gut Liver (2014) 0.86
Dioscin alleviates alcoholic liver fibrosis by attenuating hepatic stellate cell activation via the TLR4/MyD88/NF-κB signaling pathway. Sci Rep (2015) 0.85
Toll-like receptor-mediated signaling cascade as a regulator of the inflammation network during alcoholic liver disease. World J Gastroenterol (2014) 0.82
Current Management of Alcoholic Hepatitis and Future Therapies. J Clin Transl Hepatol (2016) 0.80
Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. Am J Physiol Gastrointest Liver Physiol (2016) 0.78
The Role of Innate Immunity in Alcoholic Liver Disease. Alcohol Res (2015) 0.78
Differential contribution of complement receptor C5aR in myeloid and non-myeloid cells in chronic ethanol-induced liver injury in mice. Mol Immunol (2016) 0.78
New Approaches for Studying Alcoholic Liver Disease. Curr Pathobiol Rep (2014) 0.76
Inhibition of nitric oxide production reverses diabetes-induced Kupffer cell activation and Klebsiella pneumonia liver translocation. PLoS One (2017) 0.76
Emerging concepts in alcoholic hepatitis. World J Hepatol (2017) 0.75
Heart-lung interaction via infection. Ann Am Thorac Soc (2014) 0.75
Diversity of the human intestinal microbial flora. Science (2005) 49.64
Pathogen recognition and innate immunity. Cell (2006) 44.14
Microbial ecology: human gut microbes associated with obesity. Nature (2006) 36.98
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol (2010) 24.08
Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A (2007) 20.60
Liver fibrosis. J Clin Invest (2005) 17.27
Concern Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 10.70
Intestinal mucosal barrier function in health and disease. Nat Rev Immunol (2009) 7.15
Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature (2008) 4.87
Management of cirrhosis and ascites. N Engl J Med (2004) 4.31
Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol (2004) 4.05
Bacterial translocation (BT) in cirrhosis. Hepatology (2005) 3.07
Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A (2006) 3.05
The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88. Hepatology (2008) 2.99
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology (2002) 2.93
Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. Hepatology (2001) 2.72
Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology (1995) 2.58
Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J Hepatol (2000) 2.36
Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology (1997) 2.35
Bacterial infection-related morbidity and mortality in cirrhosis. Am J Gastroenterol (2007) 2.35
The leaky gut of alcoholism: possible route of entry for toxic compounds. Lancet (1984) 2.30
Endotoxemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute alcohol excess. J Hepatol (1987) 2.28
Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology (2010) 2.23
A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology (2007) 2.16
The Mucin degrader Akkermansia muciniphila is an abundant resident of the human intestinal tract. Appl Environ Microbiol (2007) 2.09
Recent Advances in Alcoholic Liver Disease I. Role of intestinal permeability and endotoxemia in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol (2004) 2.04
Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol (2005) 1.93
Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut (2005) 1.93
Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. J Hepatol (1991) 1.91
Evidence that chronic alcohol exposure promotes intestinal oxidative stress, intestinal hyperpermeability and endotoxemia prior to development of alcoholic steatohepatitis in rats. J Hepatol (2008) 1.90
Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol (1995) 1.87
Alcohol, intestinal bacterial growth, intestinal permeability to endotoxin, and medical consequences: summary of a symposium. Alcohol (2008) 1.76
Severity of liver injury in experimental alcoholic liver disease. Correlation with plasma endotoxin, prostaglandin E2, leukotriene B4, and thromboxane B2. Am J Pathol (1993) 1.75
Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats. Alcohol Clin Exp Res (2009) 1.75
Comparison of translocation rates of various indigenous bacteria from the gastrointestinal tract to the mesenteric lymph node. J Infect Dis (1988) 1.73
Exacerbation of alcoholic liver injury by enteral endotoxin in rats. Hepatology (2000) 1.73
Intestinal integrity and Akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly. Appl Environ Microbiol (2007) 1.73
Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology (2009) 1.72
Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver (disease). Proc Soc Exp Biol Med (1994) 1.71
Activation of the innate immune system and alcoholic liver disease: effects of ethanol per se or enhanced intestinal translocation of bacterial toxins induced by ethanol? Alcohol Clin Exp Res (2005) 1.68
Ultrastructural characteristics of distal duodenum mucosa in patients with cirrhosis. Eur J Gastroenterol Hepatol (2002) 1.65
Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol (2008) 1.63
Impairment of the intestinal barrier by ethanol involves enteric microflora and mast cell activation in rodents. Am J Pathol (2006) 1.61
Effect of alcohol consumption on the gut. Best Pract Res Clin Gastroenterol (2003) 1.60
Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth. Gastroenterology (1990) 1.59
Lactobacillus GG treatment ameliorates alcohol-induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis. Alcohol (2009) 1.52
Reduced early alcohol-induced liver injury in CD14-deficient mice. J Immunol (2001) 1.50
Preventing gut leakiness by oats supplementation ameliorates alcohol-induced liver damage in rats. J Pharmacol Exp Ther (2001) 1.46
Kupffer cell sensitization by alcohol involves increased permeability to gut-derived endotoxin. Alcohol Clin Exp Res (2001) 1.44
Jejunal microflora in patients with chronic alcohol abuse. Hepatogastroenterology (1984) 1.38
Development of a new, simple rat model of early alcohol-induced liver injury based on sensitization of Kupffer cells. Hepatology (1999) 1.33
Patterns and scales in gastrointestinal microbial ecology. Gastroenterology (2009) 1.33
Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol (2001) 1.32
Alcoholic liver disease-related mortality in the United States: 1980-2003. Am J Gastroenterol (2010) 1.32
Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol (2010) 1.31
Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J Hepatol (1997) 1.31
Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites. Gastroenterology (1995) 1.28
Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology (1998) 1.27
Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology (2008) 1.27
Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem Biophys Res Commun (2008) 1.23
The detection of bacterial DNA in blood of rats with CCl4-induced cirrhosis with ascites represents episodes of bacterial translocation. Hepatology (2006) 1.22
Altered small bowel motility in patients with liver cirrhosis depends on severity of liver disease. Dig Dis Sci (1997) 1.22
Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol (2009) 1.21
LPS signaling enhances hepatic fibrogenesis caused by experimental cholestasis in mice. Am J Physiol Gastrointest Liver Physiol (2006) 1.20
Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease. Aliment Pharmacol Ther (2009) 1.19
Acetaldehyde disrupts tight junctions and adherens junctions in human colonic mucosa: protection by EGF and L-glutamine. Am J Physiol Gastrointest Liver Physiol (2005) 1.18
Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol (2008) 1.17
Acetaldehyde-induced increase in paracellular permeability in Caco-2 cell monolayer. Alcohol Clin Exp Res (1998) 1.10
Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis. J Hepatol (1994) 1.09
Long-Term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function. Am J Gastroenterol (2001) 1.08
Intestinal microflora in patients with liver cirrhosis. Chin J Dig Dis (2004) 1.08
Intragastric ethanol infusion model for cellular and molecular studies of alcoholic liver disease. J Biomed Sci (2001) 1.07
Alcohol consumption and alcoholic liver disease: evidence of a threshold level of effects of ethanol. Alcohol Clin Exp Res (1993) 1.06
Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci (1995) 1.05
Effect of acute ethanol administration on the intestinal absorption of endotoxin in rats. Alcohol Clin Exp Res (2000) 1.05
Concentrations of lipopolysaccharide-binding protein, bactericidal/permeability-increasing protein, soluble CD14 and plasma lipids in relation to endotoxaemia in patients with alcoholic liver disease. Alcohol Alcohol (2002) 1.03
Prebiotics as gut microflora management tools. J Clin Gastroenterol (2008) 1.03
Pro- and anti-inflammatory gene expression in the murine small intestine and liver after chronic exposure to alcohol. Alcohol Clin Exp Res (2001) 1.02
Infectious complications of cirrhosis. Curr Gastroenterol Rep (2001) 1.01
Association between small intestinal bacterial overgrowth and peripheral bacterial DNA in cirrhotic patients. Dig Dis Sci (2009) 1.01
Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension. Am J Gastroenterol (2003) 1.00
Experimental acute alcohol pancreatitis-related liver damage and endotoxemia: synbiotics but not metronidazole have a protective effect. Chin J Dig Dis (2005) 1.00
Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci (1996) 0.98
Probiotics and gut health: a special focus on liver diseases. World J Gastroenterol (2010) 0.96
Role of intestinal bacterial overgrowth and intestinal motility in bacterial translocation in experimental cirrhosis. Rev Esp Enferm Dig (2005) 0.95
Oats supplementation prevents alcohol-induced gut leakiness in rats by preventing alcohol-induced oxidative tissue damage. J Pharmacol Exp Ther (2009) 0.93
Bacterial translocation and gut microflora in obstructive jaundice. J Anat (1996) 0.89
Chronic ethanol intake and burn injury: evidence for synergistic alteration in gut and immune integrity. J Trauma (1995) 0.89
Presence of anti-microbial antibodies in liver cirrhosis--a tell-tale sign of compromised immunity? PLoS One (2010) 0.89
Bacterial translocation and peptidoglycan translocation by acute ethanol administration. J Gastroenterol (2002) 0.88
Luminal bacteria and small-intestinal permeability. Scand J Gastroenterol (1997) 0.84
A syndrome of cirrhosis, achlorhydria, small intestinal bacterial overgrowth, and fat malabsorption. Am J Gastroenterol (1993) 0.81
Effect of alcohol on bacterial translocation in rats. Alcohol Clin Exp Res (1998) 0.78
Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature (2008) 4.87
Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature (2012) 4.41
MyD88-mediated signals induce the bactericidal lectin RegIII gamma and protect mice against intestinal Listeria monocytogenes infection. J Exp Med (2007) 3.79
Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology (2010) 3.52
Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. J Hepatol (2012) 2.28
Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology (2010) 2.23
Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology (2008) 1.81
Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol (2011) 1.79
Dysbiosis-induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice. Hepatology (2015) 1.76
Enhanced sensitivity to DSS colitis caused by a hypomorphic Mbtps1 mutation disrupting the ATF6-driven unfolded protein response. Proc Natl Acad Sci U S A (2009) 1.69
c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice. Gastroenterology (2009) 1.59
Reduced nicotinamide adenine dinucleotide phosphate oxidase mediates fibrotic and inflammatory effects of leptin on hepatic stellate cells. Hepatology (2008) 1.53
Antiapoptotic effect of c-Jun N-terminal Kinase-1 through Mcl-1 stabilization in TNF-induced hepatocyte apoptosis. Gastroenterology (2009) 1.45
The nicotinamide adenine dinucleotide phosphate oxidase (NOX) homologues NOX1 and NOX2/gp91(phox) mediate hepatic fibrosis in mice. Hepatology (2011) 1.33
Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem Biophys Res Commun (2008) 1.23
Toll-like receptor 2-mediated intestinal injury and enteric tumor necrosis factor receptor I contribute to liver fibrosis in mice. Gastroenterology (2012) 1.20
Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice. Hepatology (2013) 1.18
Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist. Proc Natl Acad Sci U S A (2012) 1.16
Gliotoxin-mediated apoptosis of activated human hepatic stellate cells. J Hepatol (2003) 1.13
The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease. Front Physiol (2012) 1.07
Bone morphogenetic protein 7 is elevated in patients with chronic liver disease and exerts fibrogenic effects on human hepatic stellate cells. Dig Dis Sci (2007) 1.05
Inhibition of collagen alpha 1(I) expression by the 5' stem-loop as a molecular decoy. J Biol Chem (2002) 1.05
TRAM2 protein interacts with endoplasmic reticulum Ca2+ pump Serca2b and is necessary for collagen type I synthesis. Mol Cell Biol (2004) 0.99
X-linked cholestasis in mouse due to mutations of the P4-ATPase ATP11C. Proc Natl Acad Sci U S A (2011) 0.95
Alcoholic liver disease: the gut microbiome and liver cross talk. Alcohol Clin Exp Res (2015) 0.95
Non-alcoholic steatohepatitis-induced fibrosis: Toll-like receptors, reactive oxygen species and Jun N-terminal kinase. Hepatol Res (2011) 0.87
Up-regulated eotaxin plasma levels in chronic liver disease patients indicate hepatic inflammation, advanced fibrosis and adverse clinical course. J Gastroenterol Hepatol (2007) 0.86
Yip1 domain family, member 6 (Yipf6) mutation induces spontaneous intestinal inflammation in mice. Proc Natl Acad Sci U S A (2012) 0.85
CXCL5 plasma levels decrease in patients with chronic liver disease. J Gastroenterol Hepatol (2011) 0.85
Role of Gut Microbiota in Liver Disease. J Clin Gastroenterol (2015) 0.85
LPS-mediated NFkappaB activation varies between activated human hepatic stellate cells from different donors. Biochem Biophys Res Commun (2004) 0.83
Intestinal microbiota and nonalcoholic steatohepatitis. Curr Opin Gastroenterol (2017) 0.80
Enhanced Y1-receptor-mediated vasoconstrictive action of neuropeptide Y (NPY) in superior mesenteric arteries in portal hypertension. J Hepatol (2005) 0.78
Characterization of the human zinc finger protein 267 promoter: essential role of nuclear factor Y. Biochim Biophys Acta (2005) 0.77
Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease? Expert Rev Gastroenterol Hepatol (2015) 0.75